Results 251 to 260 of about 293,272 (302)

Data-informed optimization of CAR T-cell therapy long-term follow-up. [PDF]

J Immunother Cancer
Foss-Campbell B, Myers N, Awasthi R, Bechtle D, Boerstoel Streefland M, Corbett W, Dewees B, Eastwood G, Jadlowsky J, Martin LJ, Langeberg W, Lee E, Marshall A, Nichols G, Shapiro J, Shiu L, Stewart M, Tschernia NP, Willert J, Xu H, June CH.   +20 more
europepmc   +1 more source

Glycoengineering CAR-T cells to overcome galectin-3-mediated immunosuppression. [PDF]

Front Immunol
Lau LS, Suarez M, Fernandez B, Souchak J, Antonopoulos A, Hu N, Abreu MM, Koehne G, Dell A, Haslam SM, Posey AD, Dimitroff CJ.   +11 more
europepmc   +1 more source

The prospects of CAR T-cell therapies in changing the therapeutic algorithm of neurologic autoimmunities. [PDF]

Ther Adv Neurol Disord
Dalakas MC.
europepmc   +1 more source

Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma.

Blood
Luan D, Ben Valid O, Beyar-Katz O, Tix T, Accav NG, Alhomoud M, Avigdor A, Bücklein VL, Cohen L, Dahi PB, Einarsdottir S, Elimelech J, Escribano-Serrat S, Falchi L, Fei T, Giralt S, Gomez-Llobell M, Goy A, Horesh N, Israeli S, Kruk L, Leslie L, Lue JK, Marcus R, Nagler A, Palomba ML, Park JH, Raj S, Reddy S, Romancik J, Rosenbaum E, Salles G, Scordo M, Shah GL, Shimoni A, von Bergwelt-Baildon M, Perales MA, Subklewe M, Greenbaum U, Ip A, Ram R, Rejeski K, Shouval R.   +42 more
europepmc   +1 more source

RNF19B confers tumor resistance to CAR T cells

Geiger R, Vogel I, Casagranda A, Cattaneo M, Morosi L, Pecoraro M, Sulheim E, Basso C.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

CAR T Cells

Neurosurgery Clinics of North America, 2021
Chimeric antigen receptor T (CAR-T) cells, an immunotherapy that demonstrates marked success in treatment of hematologic malignancies, are an emergent therapeutic for patients with glioblastoma (GBM). GBM CAR-T trials have focused on targeting well-characterized antigens in the pathogenesis of GBM.
Thilan, Tudor, Zev A, Binder, Donald M, O'Rourke   +2 more
openaire   +2 more sources

An NK-like CAR T cell transition in CAR T cell dysfunction

Cell, 2021
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell exhaustion in the solid tumor microenvironment. To study dysfunction of mesothelin-redirected CAR T cells in pancreatic cancer, we establish a robust model of continuous antigen ...
Mª Angela Aznar, Sangya Agarwal, KENICHI ISHIYAMA   +2 more
exaly   +4 more sources

CAR T Cells

2020
In 1891, Dr. William B. Coley, an American surgeon, made a compelling observation that immune system can be triggered to shrink tumors. The quest to exploit the power of immunotherapy however was forestalled by an era of chemotherapy that ensued.
Ranjit, Nair, Jason, Westin
openaire   +3 more sources